| Similar Articles |
|---|
 |
The Motley Fool
April 26, 2011
Brian Orelli |
We Hate Your Drug. And That's a Good Thing. This one's a pain for the clinical trial participants.   |
The Motley Fool
October 31, 2007
Brian Lawler |
Alpharma's Loading Up Animal health division sales may have decreased, but the specialty drug developer is expecting renewed growth in its pharmaceutical division. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
March 29, 2010
Brian Orelli |
Look for Companies That Strike First Head-to-head trials, whether they're run by companies or by third parties, can be scary. But the way to make big money is by selling drugs that offer superior benefits, so investors should welcome the onslaught of upcoming comparative trial data. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
The Motley Fool
January 3, 2011
Brian Orelli |
Clinical Trial Results Fail to Inspire Inspire Pharma gets cut in half after a cystic fibrosis trial failure. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
July 27, 2010
Jim Mueller |
3 Stocks to Play Biotech Here are three promising ideas for this exciting area. |
The Motley Fool
April 16, 2010
Brian Orelli |
It'll Be a Blockbuster! High Fives All Around, Right? Sanofi-aventis releases top-line data for its phase 3 diabetes drug candidate, lixisenatide. The trial was a success, but don't pencil it in as a blockbuster just yet. |
The Motley Fool
June 6, 2011
Brian Orelli |
Big Pharma Tackles Lung Cancer; Biotech Helping, Too A big underserved market. |
The Motley Fool
March 8, 2010
Brian Orelli |
Really? A 59% Share Price Jump for That? Justified or not, InterMune skyrockets ahead of an FDA panel meeting. |
The Motley Fool
December 13, 2007
Brian Lawler |
Alpharma Gives to Get The generics drugmaker forecasts its 2008 financials, with guidance of expenses up and income down. |
The Motley Fool
February 28, 2008
Brian Lawler |
Alpharma on a Mission Alpharma investors take note, the company will launch its Flector pain patch this year, and has other pain drugs in its pipeline that could also make its future anything but painful. |
The Motley Fool
February 8, 2008
Brian Lawler |
Alpharma Doing Its Best Endo Imitation Alpharma sells one of its active pharmaceutical ingredient unit to help finance other businesses. |
The Motley Fool
September 8, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
August 9, 2010
Jim Mueller |
3 Stocks to Play Biotech Three promising ideas for investing in this exciting area. |
The Motley Fool
August 22, 2007
Brian Orelli |
Pain-Free Extrinsic Growth Alpharma licenses a pain-relieving patch. The launch will cut into its near-term earnings, but should help it in 2009 and beyond. Investors, take note. |
The Motley Fool
June 30, 2010
Brian Orelli |
When Researchers Attack, Investors Lose Drug investors have to watch out for a lot of things that can change their stock's price: earnings reports, clinical trial results, competitor's results, and FDA decisions. |
The Motley Fool
September 14, 2010
Luke Timmerman |
Arena Obesity Drug Effective by "Slim Margin"; Shares Tumble The market is reacting negatively to news about the company's weight-loss drug. |
The Motley Fool
July 16, 2010
Brian Orelli |
Why VIVUS Is 57% Thinner In a move that slashed the pharmaceutical's shares, Food and Drug Administration advisory committee recommended that the agency not approve their obesity drug Qnexa. |
The Motley Fool
January 28, 2010
Brian Orelli |
How to Make a Billion Bucks in Biotech Drug companies and investors alike have to balance the risk and reward. |
Chemistry World
November 2010 |
Column: In the Pipeline Should drug companies focus on big markets and the blockbuster dream? |
The Motley Fool
August 25, 2008
Brian Lawler |
King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market. |
Chemistry World
July 16, 2010
Matt Wilkinson |
Bittersweet victory for GSK's Avandia GlaxoSmithKline has received a muted 'thumbs up' from a US regulatory advisory panel for its much-maligned Type 2 diabetes drug Avandia (rosiglitazone), making it likely the US Food and Drug Administration will allow the UK-based pharma giant to continue selling the drug in the US. |
The Motley Fool
February 28, 2007
Brian Lawler |
Alpharma's Just All Right Drugmaker Alpharma announces its fourth-quarter financial results and reiterates guidance for 2007. |
The Motley Fool
August 14, 2009
Brian Orelli |
The Real King of the Drug Pushers King Pharma is first up with a tamper-resistant morphine tablet. |
The Motley Fool
March 31, 2011
Brian Orelli |
Drug Warning Labels: The Good, Bad, and Ugly Once a drug is approved, investors can't fall asleep and ignore FDA announcements about drugs. They come in different varieties, but warnings tend to be of the bad and ugly variety more often than the good. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Chemistry World
March 2011 |
Column: In the pipeline Drug discovery is an inherently risky business. Derek Lowe tries to balance some of the risk equations |
The Motley Fool
April 8, 2005
Stephen D. Simpson |
Alkermes' Alcohol Alchemy A new formulation of an old drug could help alcoholics and make shareholders happy. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch. |
American Family Physician
November 1, 2005
Steven H. Williams |
Medications for Treating Alcohol Dependence Medications for treating alcohol dependence primarily have been adjunctive interventions, and only three medications -- disulfiram, naltrexone, and acamprosate -- are approved for this indication by the U.S. Food and Drug Administration. |
The Motley Fool
April 16, 2008
Brian Lawler |
Alpharma's Soothing Guidance Alpharma lowers its financial guidance for 2008. Investors, take note. |
The Motley Fool
September 12, 2008
Brian Lawler |
King's Unstoppable Urge to Merge King Pharmaceuticals announces it has increased its offer to acquire Alpharma, and it is now taking that bid directly to the shareholders. |
